Biovica International Dirección

Dirección controles de criterios 2/4

El CEO de Biovica International's es Anders Rylander, nombrado en Jan 2011, tiene una permanencia de 13.25 años. posee directamente un 6.11% de las acciones de la empresa, con un valor de SEK8.61M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 8.3 años, respectivamente.

Información clave

Anders Rylander

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	13.3yrs
Participación del CEO	6.1%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?

Jul 18

Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation

Dec 02

Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation

Aug 02

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Feb 17

A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)

Jan 19

Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth

Nov 11

We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth

Aug 06

We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn

Mar 20

Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?

Feb 22

What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?

Jan 26

The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders

Dec 31

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Dec 05

CEO

Anders Rylander (53 yo)

13.3yrs

Permanencia

Mr. Anders Rylander serves as Chief Executive Officer of Biovica International AB (publ) since 2010. Mr. Rylander is the Founder of Arinvest and Co-Founder of Axholmen. He has been a Management Consultant...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Anders Rylander	CEO & Director	13.3yrs	sin datos	6.11% SEK 8.2m
Anders Moren	Chief Financial Officer	1.3yrs	sin datos	0.027% SEK 36.7k
Hanna Ritzén	Chief Operating Officer	1.3yrs	sin datos	0.0037% SEK 4.9k
Henrik Winther	Senior Vice President of Business Development	4.3yrs	sin datos	0.038% SEK 51.0k
Warren Cresswell	President of Americas	2.8yrs	sin datos	sin datos
Mattias Bergqvist	Vice President of Clinical Development	no data	sin datos	sin datos
Helle Fisker	Vice President of Commercial	no data	sin datos	0.026% SEK 34.6k

2.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BIOVIC B se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Anders Rylander	CEO & Director	14.3yrs	sin datos	6.11% SEK 8.2m
Lars Holmqvist	Independent Chairman of the Board	5.2yrs	kr480.00k	0.78% SEK 1.1m
Annika Berg	Independent Director	4.3yrs	kr200.00k	0.030% SEK 39.8k
Maria Holmlund	Independent Director	8.3yrs	kr250.00k	0.019% SEK 24.9k
Jarl Jungnelius	Independent Director	10.3yrs	kr200.00k	sin datos
Jesper Soderqvist	Independent Director	11.3yrs	kr230.00k	0.12% SEK 162.9k
Marie-Louise Fjallskog	Independent Director	4.3yrs	kr200.00k	sin datos

8.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de BIOVIC B se considera experimentada (8.3 años de antigüedad promedio).

Biovica International Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Insufficient new directors

Chief Financial Officer recently bought kr148k worth of stock

Insider recently bought kr149k worth of stock

Biovica International AB (publ) Appoints Anders Morén as CFO

Biovica International AB (Publ) Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022

Recent updates

New minor risk - Profitability

Forecast breakeven date pushed back to 2027

Biovica International AB (Publ) Announces Divitum® Tka in Observational Trial

New minor risk - Share price stability

Biovica International AB (publ) to Report Q4, 2025 Results on Jun 19, 2025

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Price target decreased by 21% to kr15.00

Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica International AB (publ) has completed a Composite Units Offering in the amount of SEK 119.385023 million.

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare

New major risk - Market cap size

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial

Biovica International Achieves PLA code for Medicare

New minor risk - Share price stability

Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Biovica International AB (publ) Announces A Poster with DivTum® TKa Results from the SWOG Study S0226

Third quarter 2023 earnings released

Biovica International Receives Clia Certification

Insufficient new directors

Biovica International Announces DiviTum(R) TKa Clinical Validation Data Published in Biomarkers

Chief Financial Officer recently bought kr148k worth of stock

Insider recently bought kr149k worth of stock

Second quarter 2023 earnings released

Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica International AB (publ) Appoints Anders Morén as CFO

Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch

First quarter 2023 earnings released

Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica International AB (publ) Receives FDA Approval for DiviTum®TKa

Biovica International AB (Publ) Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biovica International Announces DiviTumTKa Predicts Clinical Outcome of Patients in BioitaLEE Study

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica International AB Announces Nomination Committee Appointments

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica Announces Positive DiviTum®TKa Results from the European Multicenter Study PYTHIA Have Been Published in the Highly Ranked Peer-Reviewed Scientific Journal European Journal of Cancer

Now 23% undervalued after recent price drop

CEO & Director recently bought kr165k worth of stock

Now 21% undervalued after recent price drop

Independent Chairman of the Board recently bought kr315k worth of stock

A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth

We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth

Independent Chairman of the Board recently bought kr622k worth of stock

Forecast to breakeven in 2024

Full year 2021 earnings released: kr1.39 loss per share (vs kr1.29 loss in FY 2020)

Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma

We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn

Consensus forecasts updated

Biovica International AB (publ), Annual General Meeting, Aug 31, 2021

New 90-day low: kr39.00

Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?

FDA Resumes Review of Biovica International's Divitum®TKA Submission

CFO and Executive VP of HR & IR exercised options to buy kr421k worth of stock.

What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?

The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders

New 90-day high: kr53.60

Independent Chairman of the Board recently bought kr979k worth of stock

Analysts lower revenue estimates to kr2.50m

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Second quarter 2021 earnings released: kr0.29 loss per share

New 90-day high: kr42.00